

CITATION REPORT

List of articles citing

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease

DOI: 10.1016/j.jhep.2019.12.008
Journal of Hepatology, 2020, 72, 828-838.

Source: <https://exaly.com/paper-pdf/75309366/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
41	Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism. <i>Hepatology International</i> , 2020 , 14, 1057-1074	8.8	12
40	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Hepatology International</i> , 2020 , 14, 889-919	8.8	142
39	Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis. <i>Biomedicines</i> , 2020 , 8,	4.8	1
38	[Liver transplantation. Current aspects of pretransplantation diagnosis and rejection]. <i>Der Pathologe</i> , 2020 , 41, 505-514	1	2
37	A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2227-2240	6.7	8
36	Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	45
35	[Histopathological diagnosis and differential diagnosis of nonalcoholic fatty liver disease]. <i>Der Pathologe</i> , 2020 , 41, 434-443	1	3
34	Active Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	21
33	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. <i>Expert Opinion on Drug Discovery</i> , 2021 , 16, 125-134	6.2	0
32	Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. <i>Clinical and Molecular Hepatology</i> , 2021 , 27, 44-57	6.9	7
31	Natural History of NAFLD. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	7
30	Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. <i>Frontiers in Medicine</i> , 2021 , 8, 615978	4.9	21
29	One Week of CDAHFD Induces Steatohepatitis and Mitochondrial Dysfunction with Oxidative Stress in Liver. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
28	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021 , 41, 2076-2086	7.9	5
27	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. <i>Seminars in Liver Disease</i> , 2021 , 41, 235-247	7.3	1
26	Proof of Concept Clinical Trial of Bioimpedance-based NAFLD Diagnosis Technique. 2021 ,		0
25	MRI-Based Quantitative R2 Mapping at 3 Tesla Reflects Hepatic Iron Overload and Pathogenesis in Nonalcoholic Fatty Liver Disease Patients. <i>Journal of Magnetic Resonance Imaging</i> , 2021 ,	5.6	1

24	Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. <i>Diabetes Research and Clinical Practice</i> , 2021 , 177, 108882	7.4	0
23	Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 952-966	6.1	3
22	Perspectives of nonalcoholic fatty liver disease research: a personal point of view. 2020 , 1, 85-107		10
21	Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	5
20	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021 , 385, 1547-1558	59.2	50
19	Issues regarding NAFLD~From the changes and problems in the pathological diagnosis of NASH to the confusion of nomenclature change. <i>Acta Hepatologica Japonica</i> , 2021 , 62, 681-689	0.3	
18	Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 733348	5.9	0
17	Histological assessment based on liver biopsy: the value and challenges in NASH drug development.. <i>Acta Pharmacologica Sinica</i> , 2022 ,	8	0
16	Reliability of the Nonalcoholic Steatohepatitis Clinical Research Network and Steatosis Activity Fibrosis histological scoring systems.. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022 ,	4	0
15	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria.. <i>Frontiers in Medicine</i> , 2022 , 9, 869190	4.9	0
14	Angiogenesis Inhibitor ZM 306416 Reduces Non-Alcoholic Fatty Liver Disease in Mice Induced by High-Fat Diet. <i>Journal of Biomaterials and Tissue Engineering</i> , 2022 , 12, 1156-1163	0.3	
13	Circulating TREM2 as a non-invasive diagnostic biomarker for NASH in patients with elevated liver stiffness. <i>Hepatology</i> ,	11.2	1
12	HSPA8 Single-Nucleotide Polymorphism Is Associated with Serum HSC70 Concentration and Carotid Artery Atherosclerosis in Nonalcoholic Fatty Liver Disease. <i>Genes</i> , 2022 , 13, 1265	4.2	0
11	Endoplasmic Reticulum and Mitochondria Contacts Correlate with the Presence and Severity of NASH in Humans. 2022 , 23, 8348		1
10	Best Practices in Liver Biopsy Histologic Assessment for Nonalcoholic Steatohepatitis Clinical Trials: Expert Opinion. 2022 , 2022, 1-11		
9	Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPAR/FGF21 Axis. 2022 ,		0
8	Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity. 2022 , 100615		0
7	Microbiome-derived ethanol in nonalcoholic fatty liver disease. 2022 , 28, 2100-2106		2

- 6 Non-alcoholic fatty liver disease: the pathologist's perspective. 0
- 5 Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. **2022**, 1
- 4 The Role of Noninvasive ¹³C-Octanoate Breath Test in Assessing the Diagnosis of Nonalcoholic Steatohepatitis. **2022**, 12, 2935 0
- 3 Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. **2023**, 21, 2495-2501 0
- 2 Is it Possible to Avoid Liver Biopsy in Living Donors for Liver Transplantation by Using Two-Dimensional Shear Wave Elastography?. **2023**, 0
- 1 A Comparison of ¹³C-Methacetin and ¹³C-Octanoate Breath Test for the Evaluation of Nonalcoholic Steatohepatitis. **2023**, 12, 2158 0